Related Experiment Videos
Intravenous theophylline in pediatric status asthmaticus. A prospective, randomized, double-blind, placebo-controlled
Insights
Adding intravenous theophylline to standard asthma medications for pediatric status asthmaticus offers no clinical benefit and increases adverse effects like nausea and insomnia. Standard treatment remains effective.
Area of Science:
- Pediatric Emergency Medicine
- Pulmonology
- Pharmacology
Background:
- Pediatric status asthmaticus is a severe asthma exacerbation requiring urgent treatment.
- Current standard treatments include inhaled albuterol and intravenous methylprednisolone.
- The role of adjunctive therapies like intravenous theophylline is debated.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of adding intravenous theophylline to inhaled albuterol and intravenous methylprednisolone in pediatric patients with status asthmaticus.
Main Methods:
- A randomized, placebo-controlled trial was conducted.
- Patients aged 2-10 years with status asthmaticus received either intravenous theophylline or a placebo.
- All participants were administered aerosolized albuterol and intravenous methylprednisolone.
Main Results:
- No significant differences were observed between the theophylline and placebo groups in clinical asthma score improvement, oxygen requirements, or the number of albuterol treatments.
- Patients receiving theophylline experienced a higher incidence of adverse effects, including nausea, emesis, and insomnia.
Conclusions:
- Intravenous theophylline does not provide additional clinical benefit when added to inhaled albuterol and intravenous methylprednisolone for treating pediatric status asthmaticus.
- The addition of theophylline is associated with a significant increase in adverse events.
Abstract:
This study was conducted to determine whether intravenous theophylline, added to inhaled albuterol and intravenous methylprednisolone, provides a clinically significant benefit in the treatment of pediatric status asthmaticus. Patients aged 2 to 10 years were randomized to receive either intravenous theophylline or placebo. All patients received aerosolized albuterol and intravenous methylprednisolone. There was no difference between groups in the improvement of a clinical asthma score over time, in oxygen requirement, or in the number of albuterol treatments required. Theophylline group patients experienced more nausea, emesis, and insomnia. We conclude that there is no benefit in adding theophylline to treatment with methylprednisolone and albuterol for pediatric status asthmaticus. Furthermore, there are significantly more adverse effects associated with the use of theophylline.